Ossercon's subsidiary was the first to evaluate the use of Lansolazole for injections

Developed by Japan's Takeda Corporation, the oral preparation was first marketed in 1992, and the injectable Lansolazole, developed by TAP Pharmaceuticals, was approved by the FDA in June 2004.
company in 2001 in China to carry out the research and development of injection lanso laazole, and in 2008 the first approved listing.
In order to implement the Notice on Matters Related to the Evaluation of The Quality and Efficacy of Generic Drugs (No. 100 of 2017), the Company's subsidiaries submitted a supplementary application for conformity evaluation in January 2019 to complete the evaluation study on the quality consistency of injections of this product, and recently obtained the first notification of approval for the supplementary application for the conformity evaluation of this product.
lansolate is a new type of proton pump inhibitor (PPI), the advantage of which inhibits the secretion of stomach acid is that it can continuously improve the pH in the stomach, the acid inhibition effect is stronger, the effect is faster, can maintain a high acid suppression level throughout the day, with high cure rate, faster reduction of symptoms, less side reaction and other advantages.
injections with lansolazole can be used for the treatment of diseases such as hemorrhage-related hemorrhage of hemorrhage, gastric ulcers accompanied by bleeding, acute stress ulcers, and acute gastric mucosal lesions.
PDB database shows that in 2019 Lansolazole sales of more than 2 billion yuan, the market size.
。